News Outlets Examine Efforts To Treat TB In Ethiopia, Papua New Guinea, India

The Guardian: Ethiopia: new TB treatment means patients will no longer need a miracle
“…A scheme will see two new drugs introduced in 17 high-risk countries, including Ethiopia, with the aim of halving treatment times, eliminating the need for injections, and improving patients’ chances of a cure from 48 percent to 70 percent. Funded by UNITAID, … the $60m end-TB project will bring two drugs to the market in partnership with Médecins Sans Frontières, Interactive Research and Development, and Partners in Health…” (Kweifio-Okai, 3/24).

Inter Press Service: Multi-Drug Resistance Adds to Tuberculosis Epidemic in Papua New Guinea
“Rising multi-drug resistance in patients suffering from tuberculosis, a debilitating infectious lung disease which mainly impacts the developing world, has led to a public health emergency in the southwest Pacific Island state of Papua New Guinea, according to state officials…” (Wilson, 3/23).

Reuters: Indian doctors find success in tackling the ‘invisible burden’ of tuberculosis
“… ‘One of the things overlooked when it comes to curbing tuberculosis is the mental health problems of patients,’ said Joyce Vaghela, deputy director at St. Stephen’s Hospital’s Community Health Department. … Vaghela said the hospital’s home care mental health program has treated over 400 patients with impressive preliminary success rates, proving that psychological support is crucial…” (Bhalla, 3/24).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.